Strong Revenue Growth Driven by Procedure Volume
Revenue grew 23.0% YoY to $2.77B in Q1 FY2026, up from $2.25B in Q1 FY2025, reflecting continued adoption of the da Vinci surgical system and strong procedure volume growth across key surgical specialties globally.
Significant Operating Leverage and Margin Expansion
Operating income surged 48.0% YoY to $855.3M, with operating margin expanding approximately 520 basis points to 30.9% from 25.7%, demonstrating meaningful operating leverage as revenue growth outpaced SG&A growth of only 8.9% and R&D growth of 14.5%.
Gross Margin Improvement
Gross margin improved to 66.1% from 64.7% in the prior year period, a gain of approximately 140 basis points YoY, suggesting favorable product mix, improved manufacturing efficiencies, or pricing power in the installed base.